Development Of An Automated Cryopreservation Process For Leukapheresis To Support CGT Supply Chain

By Gautier Delwiche, Apolline Fossion, Stephanie Borensztein, Gabin Fonkou Tchinda, Yu Zhang, Javiera Bravo-Alegria and Alexandre Michaux Cryoport Systems, Villers-le-Bouillet, Belgium

Cryoport Systems, a global leader in temperature-controlled supply chain solutions for the life sciences, is advancing cell therapy manufacturing with its IntegriCell™ platform. This integrated leukapheresis supply chain platform delivers consistent, compliant, and high-quality leukapheresis starting material for cell-based therapies, optimizing manufacturing capacity while reducing risks and costs. Recognizing the importance of cryopreservation, Cryoport is building a network of centers across the US and EU to ensure close proximity to patients and to standardize the preservation of leukapheresis materials.

Through IntegriCell™, Cryoport has developed an automated, closed-system cryopreservation process for leukapheresis material, which is critical for subsequent GMP applications in cell therapy. Tests demonstrate that this optimized process ensures consistency in cell viability and recovery while preserving immune cell populations across multiple donor samples. Unlike traditional "one-size-fits-all" methods, IntegriCell™ provides a standardized approach that improves outcomes in the cell therapy manufacturing process.

Learn more by downloading the poster below.